

ARNOLD & PORTER LLP

202.942.5000
202.942.5999 Fax

555 Twelfth Street, NW
Washington, DC 20004-1206



March 27, 2007

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: U.S. Patent Application No. 10/740,694
Filed: December 22, 2003
Title: Method and Compositions for Identifying Anti-HIV Therapeutic
Compounds
Applicants: Murty N. ARIMILLI *et al.*
Atty. Docket: 18477.031

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office (USPTO):

1. a Supplemental Information Disclosure Statement (IDS);
2. a Supplemental Form PTO-1449 (listing 140 references and supplying 126 references); and
3. a Return postcard.

Please stamp the postcard with the filing date of these documents and return it to our courier.

Applicants request that the \$180.00 fee for submission of a Supplemental IDS be charged to Arnold & Porter LLP Deposit Account No. 50-2387, referencing matter number 18477.031.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned. Applicants do not believe any additional fees are due in conjunction with this filing. However, if any additional fees are

ARNOLD & PORTER LLP

Commissioner for Patents
Appln. No. 10/740,694
March 27, 2007
Page 2

required in the present application, then the Commissioner is hereby authorized to charge such fees to Arnold & Porter LLP Deposit Account No. 50-2387, referencing matter number 18477.031. A duplicate copy of this letter is enclosed.

Respectfully submitted,



David R. Marsh (Reg. No. 41,408)
Zhiqiang Zhao (Reg. No. L0117)
Lisa A. Adelson (Reg. No. 51,204)

Attachments



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Murty N. ARIMILLI *et al.*

Group Art Unit: 1648

Appln. No.: 10/740,694

Examiner: Louise W. Z. HUMPHREY

Filed: December 22, 2003

Atty. Docket: 18477.031

Title: Method and Compositions for
Identifying Anti-HIV Therapeutic
Compounds

Confirm. No.: 1095

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The attention of the Examiner is invited to consider the references listed on the attached Supplemental Form PTO-1449.

Copies of the references are submitted herewith, except that copies of the U.S. patents and published applications listed on the attached Supplemental Form PTO-1449 are not submitted herewith, in accordance with the Strategic Plan Final Rule, 69 Fed. Reg. 56481-56547 (September 21, 2004), effective October 21, 2004.

It is respectfully requested that the information above be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

03/28/2007 SZEWDIE1 00000020 502387 10740694

01 FC:1006

100.00 DA

CERTIFICATION AND/OR FEE

Because this Supplemental Information Disclosure Statement (IDS) is being submitted after issuance of the first action on the merits of the above-captioned application, a fee of \$180.00 is due pursuant to 37 C.F.R. § 1.17(p). Authorization to charge the fee for submission of this IDS is given in the accompanying transmittal letter.

Respectfully submitted,



David R. Marsh (Reg. No. 41,408)


Zhiquiang Zhao (Reg. No. L0117)

Lisa A. Adelson (Reg. No. 51,204)

Date: March 27, 2007

ARNOLD & PORTER LLP
Attn: IP Docketing
555 Twelfth Street, N.W.
Washington, D.C. 20004-1206
(202) 942-5000 telephone
(202) 942-5999 facsimile

Supplemental FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	18477.031	10/740,694
	APPLICANTS	
	Murty N. ARIMILLI <i>et al.</i>	
	FILING DATE	GROUP
	December 22, 2003	1648



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	REFERENCE PROVIDED*
	AA1	5,413,996	05/09/1995	Bodor	not required, per 69 Fed. Reg. 56481
	AB1	5,670,497	09/23/1997	Bold <i>et al.</i>	not required, per 69 Fed. Reg. 56481
	AC1	5,750,343	05/12/1998	Maag <i>et al.</i>	not required, per 69 Fed. Reg. 56481
	AD1	5,750,493	05/12/1998	Sommadossi <i>et al.</i>	not required, per 69 Fed. Reg. 56481
	AE1	5,874,577	02/23/1999	Chen <i>et al.</i>	not required, per 69 Fed. Reg. 56481
	AF1	5,914,332	06/22/1999	Sham <i>et al.</i>	not required, per 69 Fed. Reg. 56481
	AG1	6,072,053	06/06/2000	Vince <i>et al.</i>	not required, per 69 Fed. Reg. 56481
	AH1	6,312,662	11/06/2001	Erion <i>et al.</i>	not required, per 69 Fed. Reg. 56481
	AI1	6,319,946	11/20/2001	Hale <i>et al.</i>	not required, per 69 Fed. Reg. 56481
	AJ1	6,767,900	07/27/2004	Ubasawa <i>et al.</i>	not required, per 69 Fed. Reg. 56481
	AK1	2001/031773	10/18/2001	Camden	not required, per 69 Fed. Reg. 56481
	AL1	2002/0119443 A1	08/29/2002	Becker <i>et al.</i>	not required, per 69 Fed. Reg. 56481
	AM1	2003/109498	06/12/2003	Yuasa <i>et al.</i>	not required, per 69 Fed. Reg. 56481
	AN1	2004/0121316 A1	06/24/2004	Birkus <i>et al.</i>	not required, per 69 Fed. Reg. 56481

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	REFERENCE PROVIDED*	TRANSLATION
	AO1	0 267 050 A2	05/11/1988	Europe		Yes No
	AP1	0 441 192 A2	08/14/1991	Europe		x (abstract only) Yes No
	AQ1	0 465 297 A1	01/08/1992	Europe		Yes No
	AR1	0 531 597 A1	03/17/1993	Europe		Yes No
	AS1	0 632 048 A1	01/04/1995	Europe		Yes No
	AT1	0 786 455 A1	07/30/1997	Europe		Yes No
	AU1	0 852 233 A1	07/08/1998	Europe		Yes No
	AV1	0 919 562 A1	06/02/1999	Europe		Yes No
	AW1	1 295 879 A1	03/26/2003	Europe		Yes No

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. § 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.

Supplemental FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 18477.031	APPLICATION NO. 10/740,694
	APPLICANTS Murty N. ARIMILLI <i>et al.</i>	
	FILING DATE December 22, 2003	GROUP 1648

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	REFERENCE PROVIDED*	TRANSLATION
	AX1	WO 88/06158	08/25/1988	PCT		x (abstract only) Yes No
	AY1	WO 91/19721	12/26/1991	PCT		Yes No
	AZ1	WO 92/00988	01/23/1992	PCT		Yes No
	AA2	WO 92/18520	10/29/1992	PCT		x (abstract only) Yes No
	AB2	WO 93/12123	06/24/1993	PCT		Yes No
	AC2	WO 93/24510	12/09/1993	PCT		x (Abstract only) Yes No
	AD2	WO 96/14314	05/17/1996	PCT		Yes No
	AE2	WO 96/40156	12/19/1996	PCT		Yes No
	AF2	WO 97/15588 A1	05/01/1997	PCT		Yes No
	AG2	WO 98/04569	02/05/1998	PCT		Yes No
	AH2	WO 98/11906	03/26/1998	PCT		Yes No
	AI2	WO 99/62921	12/09/1999	PCT		Yes No
	AJ2	WO 00/04033	01/27/2000	PCT		Yes No
	AK2	WO 00/52015	08/09/2000	PCT		Yes No
	AL2	WO 01/13957 A2	03/01/2001	PCT		Yes No
	AM2	WO 01/13957 A3	03/01/2001	PCT		Yes No
	AN2	WO 01/17982 A1	03/15/2001	PCT		Yes No
	AO2	WO 01/19320 A2, A3	03/22/2001	PCT		Yes No
	AP2	WO 01/39724 A2	06/07/2001	PCT		Yes No
	AQ2	WO 01/39724 A3	10/18/2001	PCT		Yes No
	AR2	WO 01/46204 A1	06/28/2001	PCT		Yes No

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. § 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.

Supplemental FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 18477.031	APPLICATION NO. 10/740,694
	APPLICANTS Murty N. ARIMILLI <i>et al.</i>	
	FILING DATE December 22, 2003	GROUP 1648

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	REFERENCE PROVIDED*	TRANSLATION
	AS2	WO 01/64693 A1	09/07/2001	PCT		x (Abstract only) Yes No
	AT2	WO 01/96329 A1	12/20/2001	PCT		x (Abstract only) Yes No
	AU2	WO 01/96354 A1	12/20/2001	PCT		x (Abstract only) Yes No
	AV2	WO 02/03997 A1	01/17/2002	PCT		Yes No
	AW2	WO 02/06292 A1	01/24/2002	PCT		Yes No
	AX2	WO 02/08241 A2	01/31/2002	PCT		Yes No
	AY2	WO 02/103008 A2	12/27/2002	PCT		Yes No
	AZ2	WO 02/103008 A3	11/27/2003	PCT		Yes No
	AA3	WO 02/14344 A2	02/21/2002	PCT		Yes No
	AB3	WO 02/057425 A2	07/25/2002	PCT		Yes No
	AC3	WO 02/100415 A2, A3	12/19/2002	PCT		Yes No
	AD3	WO 03/028737 A1	04/10/2003	PCT		Yes No
	AE3	WO 03/050129 A1	06/19/2003	PCT		Yes No
	AF3	WO 03/059255 A2	07/24/2003	PCT		Yes No
	AG3	WO 03/064383 A2	08/07/2003	PCT		Yes No
	AH3	WO 03/066005 A2	08/14/2003	PCT		Yes No
	AI3	WO 03/080078 A1	10/02/2003	PCT		Yes No
	AJ3	WO 03/090690 A2	11/06/2003	PCT		Yes No
	AK3	WO 04/096234 A2	11/11/2004	PCT		Yes No
	AL3	WO 05/011709 A1	02/10/2005	PCT		Yes No

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. § 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.

Supplemental FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 18477.031	APPLICATION NO. 10/740,694
		APPLICANTS Murty N. ARIMILLI <i>et al.</i>	
		FILING DATE December 22, 2003	GROUP 1648
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			REFERENCE PROVIDED*
	AM3	Abdel-Meguid <i>et al.</i> , "Inhibition of Human Immunodeficiency Virus-1 Protease by a C ₂ -Symmetric Phosphinate. Synthesis and Crystallographic Analysis", <i>Biochemistry</i> , 32(31):7972-7980 (1993)	
	AN3	Allen <i>et al.</i> , "CI-1040 (PDI84352), a Targeted Signal Transduction Inhibitor of MEK (MAPKK)", <i>Seminars in Oncology</i> , 30(5, Suppl. 16):105-116 (2003)	
	AO3	Andrade <i>et al.</i> , "HIV-Related Drug Metabolism and Cytochrome P450 Enzymes" <i>AIDS Clinical Care</i> , 12(11):91-95 (2000)	
	AP3	Ballatore <i>et al.</i> , "Synthesis and Evaluation of Novel Amidate Prodrugs of PMEA and PMPA", <i>Bioorganic & Medicinal Chemistry Letters</i> , 11:1053-1056 (2001)	
	AQ3	Bantia <i>et al.</i> , "Purine Nucleoside Phosphorylase Inhibitor BCX-1777 (Immucillin-H)—A Novel Potent and Orally Active Immunosuppressive Agent", <i>International Immunopharmacology</i> , 1:1199-1210 (2001)	
	AR3	Beauchamp, <i>et al.</i> , "Guanine, Pyrazolo[3,4-d]pyrimidine, and Triazolo[4,5-d]pyrimidine(8-Azaguanine) Phosphonate Acyclic Derivatives as Inhibitors of Purine Nucleoside Phosphorylase", <i>Journal of Medicinal Chemistry</i> , 39:949-956 (1996)	
	AS3	Borhani <i>et al.</i> , "A-420983: A Potent, Orally Active Inhibitor of I κ B with Efficacy in a Model of Transplant Rejection", <i>Bioorganic & Medicinal Chemistry Letters</i> , 14:2613-2616 (2004)	
	AT3	Bzowska <i>et al.</i> , "Purine Nucleoside Phosphorylases: Properties, Functions, and Clinical Aspects", <i>Pharmacology & Therapeutics</i> , 88:349-425 (2000)	
	AU3	Chapman <i>et al.</i> , "Practical Synthesis, Separation, and Stereochemical Assignment of the PMPA Pro-Drug GS-7340", <i>Nucleosides, Nucleotides & Nucleic Acids</i> , 20(4-7):621-628 (2001)	
	AV3	Charvet <i>et al.</i> , "Inhibition of Human Immunodeficiency Virus Type I Replication by Phosphonoformate- and Phosphonoacetate-2',3'-Dideoxy-3'-thiacytidine Conjugates", <i>Journal of Medicinal Chemistry</i> , 37(14):2216-2223 (1994)	
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. § 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.			

Supplemental FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO.	APPLICATION NO.
		18477.031	10/740,694
		APPLICANTS	
		Murty N. ARIMILLI <i>et al.</i>	
		FILING DATE	GROUP
		December 22, 2003	1648
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			REFERENCE PROVIDED*
	AW3	Clark <i>et al.</i> , Abstract, "Mycophenolic Acid Analogues as Potential Agents Against West Nile Virus Infection", Institute for Antiviral Research, Utah State University	
	AX3	Conklyn <i>et al.</i> , "The JAK3 Inhibitor CP-690550 Selectively Reduces NK and CD8+ Cell Numbers in Cynomolgus Monkey Blood Following Chronic Oral Dosing", <i>Journal of Leukocyte Biology</i> , 76:1-8 (2004)	
	AY3	De Clercq, "Chemotherapy of Human Immunodeficiency Virus (HIV) Infection: Anti-HIV Agents Targeted at Early Stages in the Virus Replicative Cycle", <i>Biomedicine and Pharmacotherapy</i> , 50(5):207-215 (1996)	
	AZ3	De Clercq, "Highlights in the Development of New Antiviral Agents", <i>Mini Reviews in Medicinal Chemistry</i> , 2(2):163-175 (2002)	
	AA4	De Clercq, "New Developments in Anti-HIV Chemotherapy", <i>Current Medicinal Chemistry</i> , 8(13):1543-1572 (2001)	
	AB4	Dvořáková <i>et al.</i> , "Synthesis of 2'-Aminomethyl Derivatives of N-(2-(Phosphonomethoxy)ethyl) Nucleotide Analogues as Potential Antiviral Agents", <i>J. Med. Chem.</i> , 39(17):3263-3268 (1996)	
	AC4	Evans <i>et al.</i> , "Exploring Structure-Activity Relationships of Transition State Analogues of Human Purine Nucleoside Phosphorylase", <i>J. Med. Chem.</i> , 46(15):3412-3423 (2003)	
	AD4	Gobec <i>et al.</i> , Phosphonate Inhibitors of Antigen 85C, A Crucial Enzyme Involved in the Biosynthesis of the <i>Mycobacterium Tuberculosis</i> Cell Wall", <i>Bioorganic and Medicinal Chemistry Letters</i> , 14:3559-3562 (2004)	
	AE4	Gorin <i>et al.</i> , "A Novel Esterification Procedure Applied to Synthesis of Biologically Active Esters of Foscarnet", <i>Tetrahedron Letters</i> , 38(16):2791-2794 (1997)	
	AF4	Gumina <i>et al.</i> , "Advances in antiviral agents for Hepatitis B Virus", <i>Antiviral Chemistry & Chemotherapy</i> , 12(Suppl. 1):93-117 (2001)	
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. § 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.			

Supplemental FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO.	APPLICATION NO.
		18477.031	10/740,694
		APPLICANTS	
		Murty N. ARIMILLI <i>et al.</i>	
		FILING DATE	GROUP
		December 22, 2003	1648
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			REFERENCE PROVIDED*
	AG4	Hakimelahi <i>et al.</i> , "Design, Synthesis, and Structure-Activity Relationship of Novel Dinucleotide Analogs as Agents Against Herpes and Human Immunodeficiency Viruses", <i>Journal of Medicinal Chemistry</i> , 38(23):4648-4659 (1995)	
	AH4	Hammond <i>et al.</i> , "Alkylglycerol Prodrugs of Phosphonoformate are Potent In Vitro Inhibitors of Nucleoside-Resistant Human Immunodeficiency Virus Type 1 and Select for Resistance Mutations that Suppress Zidovudine Resistance", <i>Antimicrobial Agents and Chemotherapy</i> , 45(6):1621-1628 (2001)	
	AI4	Hegedus <i>et al.</i> , "Synthesis of 4'-Methyl and 4'-Cyano Carbocyclic 2',3'-Didehydro Nucleoside Analogues via 1,4-Addition to Substituted Cyclopentenones", <i>J. Org. Chem.</i> , 69(24):8492-8495 (2004)	
	AJ4	Herczegh <i>et al.</i> , "Osteoadsorbative Bisphosphonate Derivatives of Fluoroquinolone Antibacterials", <i>J. Med. Chem.</i> , 45:2338-2341 (2002)	
	AK4	Hirabayashi <i>et al.</i> , "Bone-Specific Drug Delivery Systems: Approaches via Chemical Modification of Bone-Seeking Agents", <i>Clinical Pharmacokinetics</i> , 42(15):1319-1330 (2003)	
	AL4	Holý <i>et al.</i> , "Synthesis of N-(2-Phosphonylmethoxyethyl Derivatives of Heterocyclic Bases", <i>Collect. Czech. Chem. Commun.</i> , 54:2190-2210 (1989)	
	AM4	International Search Report for International Application No. PCT/EP2003/012423, mailed February 11, 2005	
	AN4	International Search Report for International Application No. PCT/US2004/035083, mailed August 5, 2005	
	AO4	International Search Report for International Application No. PCT/US2004/035084, mailed March 2, 2005	
	AP4	International Search Report for International Application No. PCT/US2004/035085, mailed March 2, 2005	
	AQ4	Jain <i>et al.</i> , "Characterization of Pharmacological Efficacy of VX-148, a New, Potent Immunosuppressive Inosine 5'-Monophosphate Dehydrogenase Inhibitor", <i>Journal of Pharmacology and Experimental Therapeutics</i> , 302(3):1272-1277 (2002)	
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. § 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.			

Supplemental FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO.	APPLICATION NO.
		18477.031	10/740,694
		APPLICANTS	
		Murty N. ARIMILLI <i>et al.</i>	
		FILING DATE	GROUP
		December 22, 2003	1648
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			REFERENCE PROVIDED*
	AR4	Karpenko <i>et al.</i> , "Synthesis and Antiherpetic Activity of Acyclovir Phosphonates", <i>Nucleosides, Nucleotides & Nucleic Acids</i> , 22(3):319-328 (2003)	
	AS4	Kato <i>et al.</i> , "Enantio- and diasteroselective Synthesis of 4' - α -Substituted Carbocyclic Nucleosides", <i>Tetrahedron: Asymmetry</i> , 9:911-914 (1998)	
	AT4	Kato <i>et al.</i> , "Stereoselective Synthesis of 4' - α -alkylcarbovir Derivatives Based on an Asymmetric Synthesis or Chemo-Enzymatic Procedure", <i>Chemical & Pharmaceutical Bulletin</i> , 47(9):1256-1264 (1999)	
	AU4	Kilpatrick <i>et al.</i> , "Intravenous and Oral Pharmacokinetic Study of BCX-1777, a Novel Purine Nucleoside Phosphorylase Transition-State Inhibitor, <i>In vivo</i> Effects on Blood 2'-Deoxyguanosine in Primates", <i>International Immunopharmacology</i> , 3:541-548 (2003)	
	AV4	Kim <i>et al.</i> , "Regiospecific and Highly Stereoselective Electrophilic Addition to Furanoid Glycals: Synthesis of Phosphonate Nucleotide Analogues with Potent Activity Against HIV", <i>J. Org. Chem.</i> , 56(8):2642-2647 (1991)	
	AW4	Kinsky <i>et al.</i> , "Inhibition of Cell Proliferation by Putative Metabolites and Non-Degradable Analogs of Methotrexate- γ -Dimyristoylphosphatidylethanolamine", <i>Biochimica et Biophysica Acta</i> , 917(2):211-218 (1987)	
	AX4	Kinsky <i>et al.</i> , "Effect of Liposomes Sensitized with Methotrexate- γ -Dimyristoylphosphatidylethanolamine on Cells that are Resistant to Methotrexate", <i>Biochimica et Biophysica Acta</i> , 885:129-135 (1986)	
	AY4	Kinsky <i>et al.</i> , "Circumvention of the Methotrexate Transport System by Methotrexate-Phosphatidylethanolamine Derivatives Effect of Fatty Acid Chain Length", <i>Biochimica et Biophysica Acta</i> , 921:96-103 (1987)	
	AZ4	Ko <i>et al.</i> , "Efficient Synthesis of Novel Carbocyclic Nucleosides via Sequential Claisen Rearrangement and Ring-Closing Metathesis", <i>Tetrahedron Letters</i> , 43:6399-6402 (2002)	
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. § 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.			

Supplemental FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO.	APPLICATION NO.
		18477.031	10/740,694
		APPLICANTS	
		Murty N. ARIMILLI <i>et al.</i>	
		FILING DATE	GROUP
		December 22, 2003	1648
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			REFERENCE PROVIDED*
	AA5	Kofoed <i>et al.</i> , "Regiosomers of 2',3'-Dideoxynucleosides Related to 2-(Phosphonylmethoxy)ethyl Nucleosides", <i>Bulletin de la Societe Chimique de France</i> , 134:59-65 (1997)	
	AB5	Kraus, "New Phosphonate Analogues of 3'-thia-2',3'-Dideoxycytidine (BCH-189) Synthesis and Anti-HIV Evaluation", <i>Nucleosides & Nucleotides</i> , 12(2):157-162 (1993)	
	AC5	Leff <i>et al.</i> , "The Antidiabetic PPAR γ Ligands: An Update on Compounds in Development", <i>Curr. Med. Chem. - Immun., Endoc. & Metab. Agents</i> 2(1):33-47 (2002)	
	AD5	Lewandowicz <i>et al.</i> , "Achieving the Ultimate Physiological Goal in Transition State Analogue Inhibitors for Purine Nucleoside Phosphorylase", <i>The Journal of Biological Chemistry</i> , 278(34):31465-31468 (2003)	
	AE5	McGuigan <i>et al.</i> , "Synthesis and Anti-HIV Activity of Some Novel Chain-Extended Phosphoramidate Derivatives of d4T (Stavudine): Esterase Hydrolysis as a Rapid Predictive Test for Antiviral Potency", <i>Antiviral Chemistry & Chemotherapy</i> , 9:109-115 (1998)	
	AF5	McGuigan <i>et al.</i> , "Synthesis, Anti-Human Immunodeficiency Virus Activity and Esterase Lability of Some Novel Carboxylic Ester-Modified Phosphoramidate Derivatives of Stavudine (d4T)", <i>Antiviral Chemistry & Chemotherapy</i> , 9:473-479 (1998)	
	AG5	Mendes <i>et al.</i> , "Synthesis, Stability and In Vitro Dermal Evaluation of Aminocarbonyloxymethyl Esters as Prodrugs of Carboxylic Acid Agents", <i>Bioorganic & Medicinal Chemistry</i> , 10(3):809-816 (2002)	
	AH5	Menéndez-Arias, "Targeting HIV: Antiretroviral Therapy and Development of Drug Resistance", <i>TRENDS in Pharmacological Sciences</i> , 23(8):381-388 (2002)	
	AI5	Ono-Nita <i>et al.</i> , "Novel Nucleoside Analogue MCC-478 (LY582563) Is Effective Against Wild-Type or Lamivudine-Resistant Hepatitis B Virus", <i>Antimicrobial Agents and Chemotherapy</i> , 46(8):2602-2605 (2002)	
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. § 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.			

Supplemental FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO.	APPLICATION NO.
		18477.031	10/740,694
		APPLICANTS	
		Murty N. ARIMILLI <i>et al.</i>	
		FILING DATE	GROUP
		December 22, 2003	1648
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			REFERENCE PROVIDED*
	AJ5	Pankiewicz <i>et al.</i> , "Novel Mycophenolic Adenine Bis(phosphonate) Analogues As Potential Differentiation Agents Against Human Leukemia", <i>J. Med. Chem.</i> , 45(3):703-712 (2002)	
	AK5	Parang <i>et al.</i> , "Novel Approaches for Designing 5'-O-Ester Prodrugs of 3'-Azido-2', 3'-Dideoxythymidine (AZT)", <i>Current Medicinal Chemistry</i> , 7(10):995-1039 (2000)	
	AL5	Pokrovskii <i>et al.</i> , "Comparative Analysis of HIV-1 Resistance to AZT and AZT H-Phosphonate in a Cell Culture", <i>Doklady Biochemistry and Biophysics</i> , 384:152-154 (2002)	
	AM5	Prashad <i>et al.</i> , "An Efficient and Large-Scale Enantioselective Synthesis of PNP405: A Purine Nucleoside Phosphorylase Inhibitor", <i>J. Org. Chem.</i> , 67(19):6612-6617 (2002)	
	AN5	Ray <i>et al.</i> , "Role of Purine Nucleoside Phosphorylase in Interactions between 2', 3'-Dideoxyinosine and Allopurinol, Ganciclovir, or Tenofovir", <i>Antimicrobial Agents and Chemotherapy</i> , 48(4):1089-1095 (2004)	
	AO5	Roberts, "Development of the Route to the New Anti-AIDS drug Abacavir: A highlight of Academic/Industry Liaison", <i>IDrugs</i> , 1(8):896-899 (1998)	
	AP5	Rosowsky <i>et al.</i> , "Methotrexate Analogues—27", <i>Biochemical Pharmacology</i> , 35(19):3327-3333 (1986)	
	AQ5	Rosowsky <i>et al.</i> , "Methotrexate Analogues, 32, Chain Extension, α -Carboxyl Deletion, and γ -Carboxyl Replacement by Sulfonate and Phosphonate: Effect on Enzyme Binding and Cell-Growth Inhibition", <i>J. Med. Chem.</i> , 31(7):1326-1331 (1988)	
	AR5	Saboulard <i>et al.</i> , "Characterization of the Activation Pathway of Phosphoramidate Triester Prodrugs of Stavudine and Zidovudine", <i>Molecular Pharmacology</i> , 56:693-704 (1999)	
	AS5	Sauber <i>et al.</i> , "A New Esterase for the Cleavage of Pivalic Acid-Containing Prodrug Esters of Cephalosporins", <i>Enzyme and Microbial Technology</i> , 19:15-19 (1996)	
	AT5	Schultz, "Prodrugs of Biologically Active Phosphate Esters", <i>Bioorganic & Medicinal Chemistry</i> , 11:885-898 (2003)	
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. § 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.			

Supplemental FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO.	APPLICATION NO.
		18477.031	10/740,694
		APPLICANTS	
		Murty N. ARIMILLI <i>et al.</i>	
		FILING DATE	GROUP
		December 22, 2003	1648
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			REFERENCE PROVIDED*
	AU5	Sekiya <i>et al.</i> , "2-Amino-6-Arylthio-9-[2-(Phosphonomethoxy) Ethyl] Purine Bis(2,2,2-Trifluoroethyl) Esters as Novel HBV-Specific Antiviral Reagents", <i>Journal of Medicinal Chemistry</i> , 45(14):3138-3142 (2002)	
	AV5	Shi <i>et al.</i> , "Plasmodium Falciparum Purine Nucleoside Phosphorylase", <i>The Journal of Biological Chemistry</i> , 279(18):18103-18106 (2004)	
	AW5	Siddiqui <i>et al.</i> , "Design and Synthesis of Lipophilic Phosphoramidate d4T-MP Prodrugs Expressing High Potency Against HIV in Cell Culture: Structural Determinants for in Vitro Activity and QSAR", <i>Journal of Medicinal Chemistry</i> , 42(20):4122-4128 (1999)	
	AX5	Sintchak <i>et al.</i> , "The Structure of Inosine 5'-Monophosphate Dehydrogenase and the Design of Novel Inhibitors" <i>Immunopharmacology</i> , 47:163-184 (2000)	
	AY5	Srinivas <i>et al.</i> , "Metabolism and <i>In Vitro</i> Antiretroviral Activities of Bis(Pivaloyloxymethyl) Prodrugs of Acyclic Nucleoside Phosphonates", <i>Antimicrobial Agents and Chemotherapy</i> , 37(10):2247-2250 (1993)	
	AZ5	Sturtz <i>et al.</i> , "Sur une nouvelle Approche de Pharmacomodulation du Methotrexate: Synthese D'analogues Gem-Diphosphoniques D'amethoptérine et de la N-10 Deaza Amethoptérine", <i>Medicinal Chemistry, C. R. Acad. Sci. Paris</i> , 10(2):739-742 (1990)	
	AA6	Sturtz <i>et al.</i> , "Analogues Phosphonoglutamiques D'amethoptérine (Methotrexate)", <i>Eur. J. Med. Chem - Chim. Ther.</i> , 19(3):267-273 (1984)	
	AB6	Sturtz, <i>et al.</i> , "Synthesis of Gem-Bisphosphonic Methotrexate Conjugates and Their Biological Response Towards Walker's Osteosarcoma", <i>Eur. J. Med. Chem.</i> , 28:899-903 (1993)	
	AC6	Sturtz <i>et al.</i> , "A Study of the Delivery-Targeting Concept Applied to Antineoplastic Drugs Active on Human Osteosarcoma, I. Synthesis and Biological Activity in Nude Mice Carrying Human Osteosarcoma Xenografts of Gem-Bisphosphonic Methotrexate Analogues", <i>Eur. J. Med. Chem.</i> , 27(8):825-833 (1992)	
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. § 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.			

Supplemental FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO.	APPLICATION NO.
		18477.031	10/740,694
		APPLICANTS	
		Murty N. ARIMILLI <i>et al.</i>	
		FILING DATE	GROUP
		December 22, 2003	1648
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			REFERENCE PROVIDED*
	AD6	Tan <i>et al.</i> , "Sequencing and Cloning of Human Prolylcarboxypeptidase (Angiotensinase C): Similarity to Both Serine Carboxypeptidase and Prolylendopeptidase Families", <i>The Journal of Biological Chemistry</i> , 268(22):16631-16638 (1993)	
	AE6	Valette <i>et al.</i> , "Decomposition Pathways and <i>in Vitro</i> HIV Inhibitory Effects of Isodda Pronucleotides: Toward a Rational Approach for Intracellular Delivery of Nucleoside 5'-Monophosphates", <i>Journal of Medicinal Chemistry</i> , 39(10):1981-1990 (1996)	
	AF6	Vielhaber, "Bericht vom 3rd International Workshop on Salvage Therapy for HIV-Infection", <i>Deutsche Aids-Hilfe e.V. Fax Report zu HIV und AIDS</i> , Seite 4 (2000)	
	AG6	Waegell <i>et al.</i> , "A420983, a Novel, Small Molecule Inhibitor of LCK Prevents Allograft Rejection", <i>Transplantation Proceedings</i> , 34:1411-1417 (2002)	
	AH6	Wróblewski <i>et al.</i> , "Synthesis of (1R,2S)- and (1S,2S)-3-(4-Carbamoyl-1,2,3-triazol-1-yl)-1,2-Dihydroxypropylphosphonates, <i>Tetrahedron: Asymmetry</i> , 15:1457-1464 (2004)	
	AI6		
	AJ6		
	AK6		
	AL6		
	AM6		
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. § 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.			